Neil Almstead
Net Worth

Last updated:

What is Neil Almstead net worth?

The estimated net worth of Dr. Neil Almstead is at least $19,806,764 as of 2 Dec 2024. He owns shares worth $224,727 as insider, has earned $10,810,527 from insider trading and has received compensation worth at least $8,771,510 in PTC Therapeutics, Inc..

What is the salary of Neil Almstead?

Dr. Neil Almstead salary is $797,410 per year as Chief Technical Operations Officer in PTC Therapeutics, Inc..

How old is Neil Almstead?

Dr. Neil Almstead is 58 years old, born in 1967.

What stocks does Neil Almstead currently own?

As insider, Dr. Neil Almstead owns shares in one company:

Company Title Shares Price per share Total value
PTC Therapeutics, Inc. (PTCT) Chief Technical Operations Officer 4,576 $49.11 $224,727

What does PTC Therapeutics, Inc. do?

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT logo
PTCT
PTC Therapeutics, Inc.
$49.11

Neil Almstead insider trading

PTC Therapeutics, Inc.

Dr. Neil Almstead has made 52 insider trades between 2014-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 104,038 units of PTCT stock on 4 Jan 2021. As of 2 Dec 2024 he still owns at least 4,576 units of PTCT stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 2,060 $51 $105,060
Option
Common Stock 66,956 $51 $3,414,756
Option
Common Stock 2,594 $51 $132,294
Sale
Common Stock 277 $52.76 $14,615
Sale
Common Stock 1,783 $51.85 $92,449
Option
Stock Option (Right to Buy) 2,594 $51 $132,294
Option
Common Stock 2,060 $51 $105,060
Sale
Common Stock 2,328 $51.85 $120,707
Sale
Common Stock 58,345 $51.97 $3,032,190
Sale
Common Stock 8,877 $52.73 $468,040
Sale
Common Stock 28 $27.25 $763
Sale
Common Stock 618 $27.25 $16,841
Sale
Common Stock 100 $29.02 $2,902
Sale
Common Stock 1,521 $29.02 $44,132
Sale
Common Stock 53 $28.64 $1,518
Sale
Common Stock 1,236 $28.64 $35,399
Sale
Common Stock 630 $45.63 $28,746
Sale
Common Stock 28 $45.63 $1,278
Sale
Common Stock 44 $47.45 $2,088
Sale
Common Stock 27 $44.36 $1,198
Sale
Common Stock 383 $44.36 $16,990
Sale
Common Stock 27 $42.93 $1,159
Sale
Common Stock 473 $42.93 $20,307
Sale
Common Stock 716 $41.66 $29,826
Sale
Common Stock 43 $41.66 $1,791
Sale
Common Stock 632 $40 $25,281
Sale
Common Stock 43 $39.31 $1,691
Sale
Common Stock 801 $38.53 $30,859
Sale
Common Stock 64 $41.16 $2,634
Sale
Common Stock 1,001 $56.96 $57,013
Sale
Common Stock 1,001 $56.96 $57,013
Sale
Common Stock 541 $62.65 $33,895
Option
Stock Option (Right to Buy) 1,300 $27.05 $35,165
Sale
Common Stock 1,300 $27.05 $35,165
Option
Common Stock 1,300 N/A N/A
Sale
Common Stock 626 $62.37 $39,044
Sale
Common Stock 626 N/A N/A
Option
Stock Option (Right to Buy) 86,306 $35.49 $3,062,827
Option
Stock Option (Right to Buy) 86,306 N/A N/A
Option
Stock Option (Right To Buy) 11,417 N/A N/A
Option
Common Stock 104,038 N/A N/A
Option
Stock Option (Right To Buy) 11,417 $43.82 $500,282
Sale
Common Stock 91,271 $53.88 $4,917,864
Sale
Common Stock 91,271 N/A N/A
Option
Common Stock 24,062 $35.62 $856,968
Sale
Common Stock 2,187 N/A N/A
Option
Stock Option (Right to Buy) 21,875 N/A N/A
Option
Common Stock 24,062 N/A N/A
Option
Stock Option (Right To Buy) 2,187 N/A N/A
Sale
Common Stock 50,938 $32.93 $1,677,134
Option
Common Stock 50,000 N/A N/A
Sale
Common Stock 50,938 N/A N/A
Option
Stock Option (Right To Buy) 46,898 N/A N/A
Option
Common Stock 50,000 $32.93 $1,646,250
Sale
Common Stock 405 N/A N/A
Sale
Common Stock 46 N/A N/A
Sale
Common Stock 59 N/A N/A
Sale
Common Stock 634 N/A N/A
Sale
Common Stock 653 N/A N/A
Sale
Common Stock 20,000 N/A N/A
Option
Common Stock 20,000 N/A N/A
Option
Stock Option (Right To Buy) 20,000 N/A N/A
Sale
Common Stock 703 N/A N/A
Sale
Common Stock 77 N/A N/A
Sale
Common Stock 78 N/A N/A
Option
Stock Option (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 9,511 N/A N/A
Sale
Common Stock 20,370 N/A N/A
Sale
Common Stock 79 N/A N/A
Option
Stock Option (Right To Buy) 3,904 N/A N/A
Sale
Common Stock 3,904 N/A N/A
Option
Common Stock 3,904 N/A N/A
Option
Common Stock 996 N/A N/A
Sale
Common Stock 996 N/A N/A
Option
Stock Option (Right To Buy) 996 N/A N/A
Option
Common Stock 25,100 N/A N/A
Option
Stock Option (Right To Buy) 25,100 N/A N/A
Sale
Common Stock 25,100 N/A N/A
Sale
Common Stock 175 N/A N/A
Sale
Common Stock 10,859 N/A N/A

PTC Therapeutics key executives

PTC Therapeutics, Inc. executives and other stock owners filed with the SEC: